These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25965626)

  • 21. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.
    Onuma Y; Sotomi Y; Shiomi H; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Igarashi K; Kozuma K; Tanabe K; Kusano H; Rapoza R; Popma JJ; Stone GW; Simonton C; Serruys PW; Kimura T
    EuroIntervention; 2016 Oct; 12(9):1090-1101. PubMed ID: 27597270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Planned use of GP IIb/IIIa inhibitors is safe and effective during implantation of the Absorb Bioresorbable Vascular Scaffold.
    Jessup DB; Grove MM; Marks S; Kirby A
    Cardiovasc Revasc Med; 2018 Dec; 19(8):956-959. PubMed ID: 30097189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial.
    Chevalier B; Onuma Y; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; Smits PC; Kumar R; Wasungu L; Serruys PW
    EuroIntervention; 2016 Oct; 12(9):1102-1107. PubMed ID: 27564310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.
    Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F
    Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.
    Rizik DG; Hermiller JB; Kereiakes DJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):21-30. PubMed ID: 27797464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use.
    Sotomi Y; Suwannasom P; Tenekecioglu E; Tateishi H; Abdelghani M; Serruys PW; Onuma Y
    Expert Rev Cardiovasc Ther; 2015 Oct; 13(10):1127-45. PubMed ID: 26401921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioresorbable vascular scaffold for coronary in-stent restenosis: a novel concept.
    Deora S; Shah S; Pancholy S; Patel T
    Indian Heart J; 2014; 66(4):459-61. PubMed ID: 25173206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry.
    Capodanno D; Gori T; Nef H; Latib A; Mehilli J; Lesiak M; Caramanno G; Naber C; Di Mario C; Colombo A; Capranzano P; Wiebe J; Araszkiewicz A; Geraci S; Pyxaras S; Mattesini A; Naganuma T; Münzel T; Tamburino C
    EuroIntervention; 2015 Feb; 10(10):1144-53. PubMed ID: 25042421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions.
    Naganuma T; Kawamoto H; Panoulas VF; Latib A; Tanaka A; Mitomo S; Ruparelia N; Jabbour RJ; Chieffo A; Carlino M; Montorfano M; Colombo A
    Int J Cardiol; 2017 Nov; 246():26-31. PubMed ID: 28867010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
    Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
    JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial.
    Gao R; Yang Y; Han Y; Huo Y; Chen J; Yu B; Su X; Li L; Kuo HC; Ying SW; Cheong WF; Zhang Y; Su X; Xu B; Popma JJ; Stone GW;
    J Am Coll Cardiol; 2015 Dec; 66(21):2298-2309. PubMed ID: 26471805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?
    Rizik DG; Hermiller JB; Simonton CA; Klassen KJ; Kereiakes DJ
    Coron Artery Dis; 2017 Jan; 28(1):77-89. PubMed ID: 27561169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis.
    Lipinski MJ; Escarcega RO; Baker NC; Benn HA; Gaglia MA; Torguson R; Waksman R
    JACC Cardiovasc Interv; 2016 Jan; 9(1):12-24. PubMed ID: 26762906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis.
    Zhang XL; Zhu L; Wei ZH; Zhu QQ; Qiao JZ; Dai Q; Huang W; Li XH; Xie J; Kang LN; Wang L; Xu B
    Ann Intern Med; 2016 Jun; 164(11):752-63. PubMed ID: 27042809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry.
    Kraak RP; Hassell ME; Grundeken MJ; Koch KT; Henriques JP; Piek JJ; Baan J; Vis MM; Arkenbout EK; Tijssen JG; de Winter RJ; Wykrzykowska JJ
    EuroIntervention; 2015 Feb; 10(10):1160-8. PubMed ID: 25136885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Everolimus-eluting bioresorbable vascular scaffolds versus second generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the GHOST-CTO registry.
    La Manna A; Chisari A; Giacchi G; Capodanno D; Longo G; Di Silvestro M; Capranzano P; Tamburino C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):E155-E163. PubMed ID: 26756959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioresorbable vascular scaffold thrombosis in a consecutive cohort of 550 patients.
    Tröbs M; Achenbach S; Röther J; Klinghammer L; Schlundt C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):872-880. PubMed ID: 27142643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early and late optical coherence tomography findings following everolimus-eluting bioresorbable vascular scaffold implantation in myocardial infarction: a preliminary report.
    Karanasos A; Muramatsu T; Diletti R; Nauta S; Onuma Y; Lenzen M; Nakatani S; Van Mieghem NM; Schultz C; De Jaegere PP; Serruys PW; Zijlstra F; Regar E; van Geuns RJ
    Hellenic J Cardiol; 2015; 56(2):125-35. PubMed ID: 25854441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low major adverse cardiac event rates following bioresorbable vascular scaffold implantation: Impact of implantation technique on treatment outcomes.
    Ganeshkumar AV; Patil RS; Hamid IK
    Indian Heart J; 2018; 70(1):10-14. PubMed ID: 29455763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of everolimus eluting bioabsorbable vascular scaffold (BVS) compared to non BVS drug eluting stent in the management of ST-segment elevation myocardial infarction (STEMI) - A comparative study.
    Chakraborty R; Patra S; Banerjee S; Pande A; Khan A; Mandol PC; Ghosh D; De SK; Das SS; Nag R
    Cardiovasc Revasc Med; 2016; 17(3):151-4. PubMed ID: 26905052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.